SCHEMBL10034797

SCHEMBL10034797

C=C(O[Si](C)(C)C)c1ccc2c(c1)OCCOCCOCCOCCOCCOc1cc-2ccc1C(=C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.38
▸ MAPT P10636 2/20 0.36
▸ LMNA P02545 2/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ CSNK2A1 P68400 5/20 0.34
▸ CSNK2A2 P19784 2/20 0.33
▸ STK17A Q9UEE5 2/20 0.31
▸ GAK O14976 1/20 0.31
▸ STK17B O94768 1/20 0.31
▸ BMP2K Q9NSY1 1/20 0.31
▸ POLB P06746 2/20 0.31
▸ RECQL P46063 1/20 0.31
▸ BLM P54132 1/20 0.31
▸ L3MBTL1 Q9Y468 1/20 0.31
▸ NPSR1 Q6W5P4 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ ALOX15 P16050 1/20 0.31
▸ ALOX12 P18054 1/20 0.31
▸ HTT P42858 1/20 0.31
▸ CLK1 P49759 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL881633 0.93 KDM4E (0.36) KDM4EMAPTLMNAKMT2ACSNK2A1
SCHEMBL10034793 0.85 KDM4E (0.43) KDM4EMAPTLMNAKMT2APOLB
SCHEMBL10034796 0.85 POLB (0.35) KDM4EMAPTLMNAKMT2ACSNK2A1
SCHEMBL881347 0.84 KDM4E (0.44) KDM4EMAPTLMNAKMT2APOLB
SCHEMBL10067201 0.79 ALOX5 (0.37) KDM4EMAPTLMNAKMT2ACSNK2A1
SCHEMBL881625 0.75 KDM4E (0.61) KDM4EMAPTLMNAKMT2ACSNK2A1
SCHEMBL881622 0.68 KDM4E (0.41) KDM4EMAPTL3MBTL1NPSR1ALDH1A1
SCHEMBL10034802 0.64 KDM4E (0.54) KDM4EMAPTLMNAKMT2APOLB
SCHEMBL881325 0.64 KDM4E (0.78) KDM4EMAPTLMNAKMT2APOLB
SCHEMBL21450877 0.63 POLB (0.54) KDM4EMAPTLMNAKMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822520-B2 Substituted bicyclic HCV inhibitors PRESIDIO PHARMACEUTICALS, INC. (US) 2014-09-02 — — US disclosed
US-20130178507-A1 SUBSTITUTED BICYCLIC HCV INHIBITORS PRESIDIO PHARMACEUTICALS, INC. (US) 2013-07-11 — — US disclosed
US-20120028978-A1 SUBSTITUTED BICYCLIC HCV INHIBITORS PRESIDIO PHARMACEUTICALS, INC. (US) 2012-02-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130178507-A1 SUBSTITUTED BICYCLIC HCV INHIBITORS HAVCR2, LIPC, EIF2AK2 KDM4E 3798/4885MAPT 3596/4885LMNA 3390/4885
US-20120028978-A1 SUBSTITUTED BICYCLIC HCV INHIBITORS HAVCR2, LIPC, EIF2AK2 KDM4E 3798/4885MAPT 3596/4885LMNA 3390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback